New imaging tracks cancer drug in body
NCT ID NCT05638334
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, not to test if it works as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- S095012 (a bispecific antibody targeting PD-L1 and 4-1BB) and a radioactive tracer (89Zr-S095012)
- What this could lead to
- If successful, this imaging approach could help doctors see which patients might benefit from S095012 treatment.
- What could go wrong
- This was a very small, early-phase study (only 3 participants) that was terminated early, so results are limited and may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UMC Gronningen Oncologie
Groningen, 9713 AZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?